Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant hormonal deprivation before radical prostatectomy

C C Schulman1, A M Sassine

  • 1Department of Urology, Erasme Hospital, University Clinics of Brussels, Belgium.

European Urology
|January 1, 1993
PubMed
Summary

Preoperative androgen blockade in prostate cancer patients significantly reduced prostate volume, aiding surgery. Post-treatment undetectable PSA levels strongly predicted organ-confined disease, suggesting value in patient selection for radical prostatectomy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erectile dysfunction and cardiovascular diseases.

Archivos espanoles de urologia·2010
Same author

To the German Society of Urology - centennial celebration.

Der Urologe. Ausg. A·2006
Same author

A simple maneuver to replace dislodged laparoscopic port.

Urology·2004
Same author

Handling and reporting of biopsy and surgical specimens of testicular cancer.

European urology·2004
Same author

[Laparoscopy in urology].

Revue medicale de Bruxelles·2003
Same author

Early prostate cancer: prevention, treatment modalities, and quality of life issues.

European urology·2003

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Preoperative hormonal deprivation before radical prostatectomy is debated.
  • Potential benefits include downstaging, downgrading, improved surgical outcomes, and increased survival.

Purpose of the Study:

  • To evaluate the impact of preoperative androgen blockade on prostate volume, surgical dissection, pathological staging, and prostate-specific antigen (PSA) levels.
  • To assess the predictive value of post-treatment PSA for tumor stage.

Main Methods:

  • Retrospective analysis of 100 radical prostatectomy patients.
  • 40 patients received complete preoperative androgen blockade (luteinizing-hormone-releasing hormone agonist and flutamide).
  • Assessed prostate volume changes, clinical and pathological staging, and PSA levels pre- and post-treatment.

Related Experiment Videos

Main Results:

  • Preoperative androgen blockade reduced prostate volume by 40-50%, facilitating surgical dissection.
  • Clinical downstaging occurred in one-third of patients, but pathological staging did not consistently confirm this.
  • PSA dropped to undetectable levels in 59% of patients; 86% of these had organ-confined (PT2) tumors.
  • Patients with PSA > 4 ng/ml post-treatment all had advanced (PT3-PT4) disease.

Conclusions:

  • Preoperative androgen blockade effectively reduces prostate volume and may aid surgical dissection.
  • Post-neoadjuvant therapy PSA levels appear to be a valuable predictor of pathological tumor stage.
  • Undetectable PSA after treatment correlates with a high likelihood of organ-confined disease, aiding patient selection for radical prostatectomy.